Clinical trial
Taxoprexin Treatment for Advanced Skin Melanoma
NCT00249262 · American Regent, Inc., Industry · Completed
Key facts
| NCT number | NCT00249262 |
|---|---|
| Title | Taxoprexin Treatment for Advanced Skin Melanoma |
| Official title | Phase II Open-Label Study of Weekly Taxoprexin (DHA-paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-choroidal Melanoma |
| Lead sponsor | American Regent, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Melanoma |
| Intervention type | Drug |
| Interventions | Taxoprexin |
| Enrollment | 30 |
| Start date | Oct 1, 2005 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Nov 7, 2005 |
| Last update posted | Sep 26, 2025 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: